We are proud to have contributed to the careers of the following former lab members:

  • Hui Zhao Post-Doc (2011-2019; FWO funding); First authorship in Elife. 2014 Aug 1;3:e02725. Current position: Senior Bioinformatics Analyst position in Cancer Research UK.
     
  • Flora d'Anna, PhD (2014-2018); The Two-Way Interaction Between Tumour Hypoxia And DNA Methylation’; Shared first authorship in Nature. 2016 Sep 1;537(7618):63-68. Current position: Research Data Manager at ELIXIR.
     
  • Xiaowen Chen (Feb 2018): ‘The Role of Mevalonate Metabolism and Blood Flow in Developmental Angiogenesis’.
     
  • Bernard Thienpont, Post-Doc (2012-2017; FWO-funding). First authorship in Nature. 2016 Sep 1;537(7618):63-68. Current position: Professor Laboratory for Functional Epigenetics; Department of Human Genetics
     
  • Dominiek Smeets, PhD (2009-2019): ‘Tumor heterogeneity in relapsed or metastatic breast, ovarian and colorectal cancer’; First authorship in Nat Commun. 2018 Oct 5;9(1):4112. Current position: Field Application Scientist at Illumina.
     
  • Jeroen Depreeuw, PhD (2013-2017): ‘New molecular insights based on genetic alterations in gynecological cancers’; First authorship in Clin Cancer Res. 2017 Dec 1;23(23):7232-7241. Current position: data scientist at Biocartis.
     
  • Els Wauters (Dec 2015; FWO funding): ‘Exploring the common genetic and epigenetic basis for COPD, emphysema and lung cancer’; First authorship in Eur. Heart J. 2013 Apr;34(13):993-1001. Current position: Staff member UZ Leuven, pneumo-oncologist and assistant professor KU Leuven.
     
  • Matthieu Moisse, PhD (Nov 2015; FWO funding); ‘Next generation sequencing: a tool to reveal the genetic origin of human diseases’; First authorship in Human Molecular Genetics 1;21(11):2412-9; 2012. Current position: post-doc KU Leuven.
     
  • Betül Tuba Yesilyurt, PhD (2008-2013); Functional validation of recurrent mutations in microsatellite instable endometrial tumors.
     
  • Bart Claes, PhD (2008-2012); Identification and functional study of a VEGFR-1 locus predicting bevacizumab treatment outcome (IWT funding); First authorship publication: A genetic locus in VEGFR-1 predicts bevacizumab treatment outcome in randomised phase III studies of metastatic pancreatic cancer and renal cell carcinoma. Lancet Oncology; 13 (7): 724-33, 2012. Current employer: Biocartis where he serves as a Scientist Oncology and is responsible for oncology biomarker assay development.
     
  • Joke Reumers, Post-Doc (2009-2012); A pipeline for the analysis of full cancer genomes (FWO funding); First authorship publication: Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. Nature Biotechnology; 30(1):61-68, 2011. Current employer: Janssen Pharmaceutica where she is responsible for DNA and RNA analyses.
     
  • Joke Dhondt (2007-2011); The protective effect of VEGF-B and its receptor FLT1 in peripheral neuropathy (IWT funding); First authorship publication: Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons. Faseb J; 25(5):1461-1473, 2011. Current employer: Universal Medica (Paris), where she works as a Scientific Coordinator.
     
  • An Verheyen, PhD (2007-2011); The role of VEGF in paclitaxel - induced peripheral neuropathy (IWT funding); First authorship publication: Systemic anti-VEGF therapies induce a painful sensory neuropathy. Brain; 135 (Pt 9): 2629-41, 2012. Current employer: Janssen Pharmaceutica 
     
  • Ian Buysschaert (2006-2010); Phenotypic Dissection of the Chromosome 9p21.3 Locus in Atherosclerosis and Ischemic Heart Disease (IWT funding); First authorship publication: A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: The GRACE Genetics Study. European Heart Journal; 31(9):1132-1141. Ian Buysschaert is currently completing his specialization as a cardiologist at ZNA Middelheim in Antwerpen.
     

Alumni PhD students (co-promotor):

  • Adriaan Vanderstichele (Jan 2019): ‘Liquid biopsies in ovarian cancer: clinical applications of cell-free DNA analysis’; First authorship in Clin Cancer Res. 2017 May 1;23(9):2223-2231. Current position: Staff member UZ Leuven, Gynaecologist-Oncologist.
     
  • Line Heylen(Sept 2017): ‘Ischemia in kidney transplantation: clinical risk factor and epigenetic modifier’; First authorship in Kidney Int. 2019 Nov;96(5):1195-1204. Current position: nephrologist at ZOL Hospital Genk, Belgium.
     
  • Michael Olvedy(Jun 2017): ‘Integrative and comparative genomics identifies novel melanoma tumor-suppressor genes’; First authorship in J Clin Invest. 2017 Jun 1;127(6):2310-2325. Current position: Junior Policy Officer - Blue Book trainee at ERCEA.
     
  • Tine Cuppens (Jun 2017): ‘Identification of novel potential therapeutic targets in uterine sarcomas - From human sample analysis to preclinical validation’; First authorship in Int J Cancer. 2018 Mar 15;142(6):1230-1243. Current position: Medical Science Liaison Oncology at AstraZenica.
     
  • Barbara Brouwers (Jun 2016): ‘Study on tumor biology and the aging effect of chemotherapeutic treatment in older breast cancer patients’; First authorship in Breast Cancer Res. 2017 Jul 3;19(1):78. Current position: oncologist AZ Sint-Jan Hospital, Bruges, Belgium.
     
  • Evelyn Despierre (Dec 2015): ‘Role of genomic alterations as prognostic and predictive factors in epithelial ovarian cancer’; First authorship in Target Oncol. 2015 Dec;10(4):583-96. Current position: gynaecologist at OLV Hospital Aalst, Belgium.
     
  • Sandrina Lambrechts (Nov 2015): ‘Genetic alterations guiding ovarian cancer therapy’; First authorship in Eur J Cancer. 2016 Jan;53:51-64. Current position: gynaecologist-oncologist at Maastricht UMC+.
     
  • Stefanie Schrauwen (Apr 2015): ‘Establishment of preclinical endometrial carcinoma models and evaluation of new treatment options’; First authorship in Gynecol Oncol. 2015 Jul;138(1):165-73. Current position: Protocol Manager at Bristol-Myers Squibb.
     
  • Andrés García Dios(Jun 2013): ‘Somatic mutations and copy number alterations as prognostic markers for primary endometrial cancer’; First authorship in Gynecol Oncol. 2013 Feb;128(2):327-34.